| Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ... Journal of Clinical Oncology 36 (3), 276-282, 2018 | 725 | 2018 |
| Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients T Hackert, M Sachsenmaier, U Hinz, L Schneider, CW Michalski, ... Annals of surgery 264 (3), 457-463, 2016 | 555 | 2016 |
| Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients N Halama, I Zoernig, A Berthel, C Kahlert, F Klupp, M Suarez-Carmona, ... Cancer cell 29 (4), 587-601, 2016 | 507 | 2016 |
| Pancreatic cancer surgery: the new R-status counts O Strobel, T Hank, U Hinz, F Bergmann, L Schneider, C Springfeld, ... Annals of surgery 265 (3), 565-573, 2017 | 362 | 2017 |
| Chemotherapy for pancreatic cancer C Springfeld, D Jäger, MW Büchler, O Strobel, T Hackert, DH Palmer, ... La Presse Médicale 48 (3), e159-e174, 2019 | 290 | 2019 |
| Advanced-stage pancreatic cancer: therapy options J Werner, SE Combs, C Springfeld, W Hartwig, T Hackert, MW Büchler Nature reviews Clinical oncology 10 (6), 323-333, 2013 | 290 | 2013 |
| A ferret model of canine distemper virus virulence and immunosuppression V Von Messling, C Springfeld, P Devaux, R Cattaneo Journal of virology 77 (23), 12579-12591, 2003 | 261 | 2003 |
| NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer C Heining, P Horak, S Uhrig, PL Codo, B Klink, B Hutter, M Fröhlich, ... Cancer discovery 8 (9), 1087-1095, 2018 | 241 | 2018 |
| Neoadjuvant therapy for pancreatic cancer C Springfeld, CR Ferrone, MHG Katz, PA Philip, TS Hong, T Hackert, ... Nature Reviews Clinical Oncology 20 (5), 318-337, 2023 | 217 | 2023 |
| Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic … P Ghaneh, D Palmer, S Cicconi, R Jackson, CM Halloran, C Rawcliffe, ... The lancet Gastroenterology & hepatology 8 (2), 157-168, 2023 | 206 | 2023 |
| Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation P Devaux, V von Messling, W Songsungthong, C Springfeld, R Cattaneo Virology 360 (1), 72-83, 2007 | 205 | 2007 |
| Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? U Heger, S Blank, C Wiecha, R Langer, W Weichert, F Lordick, T Bruckner, ... Annals of surgical oncology 21, 1739-1748, 2014 | 120 | 2014 |
| Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine C Grossardt, CE Engeland, S Bossow, N Halama, K Zaoui, MF Leber, ... Human gene therapy 24 (7), 644-654, 2013 | 117 | 2013 |
| Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases C Springfeld, V Von Messling, M Frenzke, G Ungerechts, CJ Buchholz, ... Cancer research 66 (15), 7694-7700, 2006 | 111 | 2006 |
| Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine G Ungerechts, C Springfeld, ME Frenzke, J Lampe, PB Johnston, ... Cancer research 67 (22), 10939-10947, 2007 | 104 | 2007 |
| Actual five-year survival after upfront resection for pancreatic ductal adenocarcinoma: who beats the odds? O Strobel, P Lorenz, U Hinz, M Gaida, AK Koenig, T Hank, W Niesen, ... Annals of surgery 275 (5), 962-971, 2022 | 103 | 2022 |
| Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma B Goeppert, S Roessler, M Renner, S Singer, A Mehrabi, MN Vogel, ... British journal of cancer 120 (1), 109-114, 2019 | 101 | 2019 |
| An immunocompetent murine model for oncolysis with an armed and targeted measles virus G Ungerechts, C Springfeld, ME Frenzke, J Lampe, WB Parker, ... Molecular Therapy 15 (11), 1991-1997, 2007 | 101 | 2007 |
| Pancreatic ductal adenocarcinoma subtyping using the biomarkers hepatocyte nuclear factor-1A and cytokeratin-81 correlates with outcome and treatment response A Muckenhuber, AK Berger, AM Schlitter, K Steiger, B Konukiewitz, ... Clinical Cancer Research 24 (2), 351-359, 2018 | 97 | 2018 |
| Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis TS Miest, KC Yaiw, M Frenzke, J Lampe, AW Hudacek, C Springfeld, ... Molecular Therapy 19 (10), 1813-1820, 2011 | 88 | 2011 |
